KDU691

KDU691 (CAS No.: 1513879-19-0) is an imidazopyrazine-class antimalarial agent characterized by potent, multi-stage antiparasitic activity and primarily employed in biomedical research targeting Plasmodium phosphatidylinositol 4-kinase (PI4K). This compound selectively inhibits parasite PI4K, a key regulator of phosphoinositide signaling essential for membrane biogenesis and intracellular development, thereby disrupting parasite replication across blood-stage schizonts, gametocytes, and liver-stage forms. KDU691 demonstrates high potency against recombinant Plasmodium PI4K with activity in the nanomolar range and exhibits marked selectivity over a broad panel of human lipid and protein kinases, indicating a favorable target specificity profile. In vitro, it effectively suppresses multiple Plasmodium species, including P. falciparum and P. vivax, and shows activity against both replicative and dormant liver-stage forms such as hypnozoites, with inhibitory effects generally observed from nanomolar to low micromolar concentrations. Notably, it preferentially inhibits ring-stage parasites following dihydroartemisinin pretreatment, suggesting utility in combination therapy strategies and resistance biology studies. In vivo studies in nonhuman primate models indicate that KDU691 can prevent establishment of infection, although it may not fully eradicate established parasitemia under certain conditions. This compound is widely used in antimalarial drug discovery, target validation, and life cycle biology research, with experimental concentrations or dosing regimens varying depending on assay systems, parasite stage, and study objectives.